[Clinical experimentation on the tolerance and efficacy of Lamuran administered by phleboclysis in 39 patients with peripheral vascular diseases].
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000188:drug therapy*; D001663:Bilirubin / Q000097:blood; D002784:Cholesterol / Q000097:blood; D003925:Diabetic Angiopathies / Q000188:drug therapy; D004361:Drug Tolerance; D005260:Female; D005734:Gangrene / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D007383:Intermittent Claudication / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010946:Plants, Medicinal; D011926:Rauwolfia / Q000008:administration & dosage* / Q000494:pharmacology; D011928:Raynaud Disease / Q000188:drug therapy; D012881:Skin Temperature / Q000187:drug effects; D000637:Transaminases / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014652:Vascular Diseases / Q000188:drug therapy; D014665:Vasodilator Agents / Q000008:administration & dosage*
D008055:Lipids; D014280:Triglycerides; D014665:Vasodilator Agents; D002784:Cholesterol; D000637:Transaminases; D001663:Bilirubin
Sperimentazione clinica sulla tollerabilità ed efficacia del Lamuran per fleboclisi in 39 pazienti vasculopatici periferici.